Case History: A 74-year-old male was diagnosed with stage IV lung adenocarcinoma. Pathology results were wild-type for EGFR/ALK/ROS1 (using a hotspot lung panel) with high PD-L1 expression. Based on these results, the patient received 4 cycles of immune checkpoint inhibitor (PD-L1). Immunotherapy treatment was discontinued due to pseudoprogression, and later MRI confirmed disease progression. At…

Case History An 80-year-old male was diagnosed with metastatic prostate cancer when he presented with back pain. PSMA-based PET imaging showed oligometastatic disease with nodal and bone lesions. The patient received radiotherapy and started on androgen deprivation therapy plus upfront docetaxel and completed 8 cycles, then therapy was switched to enzalutamide. PSA initially improved and…

Case History: A 72-year-old female previously diagnosed with breast cancer was presented with lung and extensive bone secondaries. Histopathology test confirmed invasive ductal carcinoma; ER negative, PR negative, Her2neu2- positive. She was started on palliative chemotherapy with trastuzumab + pertuzumab + docetaxel and completed 12 cycles. PET CT showed a good response, and she was…

Case history: 7-year old boy was diagnosed with high-risk neuroblastoma involving right adrenal mass, bone marrow and multiple bony sites. He was treated with as per high-risk-neuroblastoma-1/ESIOP protocol and remained disease free for three years. Cyclophosphamide-topotecan based chemotherapy was administered when he relapsed in the bone marrow as salvage therapy. No change in disease status…

Case history: 68-year old male diagnosed with EGFR-mutated lung adenocarcinoma (Del19). Started on 2nd generation EGFR TKI, 9 months later CT scan showed disease progression in CN. Plasma PCR-based testing showed a new EGFR T790M mutation. Treatment changed to 3rd generation EGFR TKI due to liquid findings and the patient’s partial respons. CT scan 7…

Case History: Genomic Profiling Results: Additional Biomarker Results: Questions from the oncologist: Interpretation:  First, advise the oncologist that patient support and advocacy groups exist for patients with cholangiocarcinoma at https://lnkd.in/gHHsEkK and the biomarkercollaborative.org. Germline or somatic BRCA mutations are increasingly described in biliary tract cancer (BTC)(1) and these mutations, like in other tumor types, have been shown to result in…